Magtech: Costs and benefits of Magtrace® in breast surgery
Research type
Research Study
Full title
MagTech: Cost Effectiveness and benefits of Magtrace® versus Technetium in sentinel node biopsy for breast cancer
IRAS ID
293053
Contact name
James Harvey
Contact email
Sponsor organisation
Manchester University NHS Foundation Trust
ISRCTN Number
ISRCTN11807786
Clinicaltrials.gov Identifier
ISRCTN application made , 41566
Duration of Study in the UK
1 years, 3 months, 1 days
Research summary
Women with a small breast cancer require surgery to remove the cancer from their breast and also to remove a few lymph nodes from their armpit (sentinel node biopsy) at the same time to see whether the cancer has spread. These women have an injection of a dye before their surgery which demonstrates the lymph nodes the surgeon needs to remove. This study aims to compare the cost-effectiveness of two commonly used types of dye for sentinel node biopsy - Magtrace and technetium. 50 patients will be randomized to have either Magtrace or Technetium. A research assistant will shadow these women in their visits to the hospital prior to surgery and work out the hospital costs associated with each treatment. The second phase of the study is a questionnaire of patients and healthcare professionals, asking them what their preferences are in how this type of care is best delivered.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
22/NW/0192
Date of REC Opinion
27 Sep 2022
REC opinion
Further Information Favourable Opinion